Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase

David M. Smadja, Qun-Ying Yue, Richard Chocron, Olivier Sanchez, Agnes Lillo-Le Louet
European Respiratory Journal 2021; DOI: 10.1183/13993003.00956-2021
David M. Smadja
1Université de Paris, Innovative Therapies in Hemostasis, INSERM, Paris, France; Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
2F-CRIN INNOVTE network, Saint Etienne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qun-Ying Yue
3Uppsala Monitoring Centre, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Chocron
4Emergency Department, Université de Paris, PARCC, INSERM U970, AH-HP-Centre Université de Paris (APHP-CUP), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Chocron
Olivier Sanchez
2F-CRIN INNOVTE network, Saint Etienne, France
5Université de Paris, Innovative Therapies in Hemostasis, INSERM, Paris, France; Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agnes Lillo-Le Louet
6Université de Paris, Innovative Therapies in Hemostasis, INSERM, Paris, France; Pharmacovigilance Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

we observed an imbalance between venous and arterial thrombotic events in mRNA vaccines while with AZ1222 they are evenly shared. Our analysis highlights cerebral vein thrombosis with the three vaccin.

To the Editor

COVID-19 is associated with a prothrombotic phenotype characterised by coagulopathy and endothelial dysfunction [1–4]. Following some cases of thrombosis after vaccination, Oxford-AstraZeneca vaccine (AZD1222) was temporarily suspended by some European countries. The European medicines agency (EMA) concluded that the benefits of the vaccine in combating COVID-19 outbreak continue to outweigh the risk of side effects. On March 19, 2021, Germany reported 13 cases of sinus or cerebral vein thrombosis with more than 1.6 million AstraZeneca COVID-19 vaccine doses administered. Some of these patients also had a heparin-induced thrombocytopenia (HIT)-like syndrome, which does suggest an immunological event as one of the potential origin of thrombosis.

Here, we provide a descriptive analysis of the anti-SARS-CoV-2 vaccination thrombotic risk reported to the World Health Organisation (WHO) Global Database for Individual Case Safety Reports (VigiBase). VigiBase is a databank developed and maintained by the Uppsala Monitoring Centre (UMC), Sweden. It is the world's largest pharmacovigilance database with submission from member states since the establishment of the WHO Program for International Drug Monitoring in 1968. Vigibase has been largely used in the past years to detect significant signals for adverse drugs reaction (ADRs) [5]. Some ADRs may be identified only after vaccine commercialisation, in particular when they are very rare or have a delayed time to onset. Therefore, the safety monitoring of vaccines continues in post marketing surveillance. For example, during the mass vaccination campaign in 2009 for H1N1, several cases of narcolepsia have been reported during post marketing period [6].

In this context, our study aims at assessing clinical features of arterial and venous thrombosis after injection of three anti-COVID-19 vaccines (Comirnaty® from Pfizer-BioNtech; COVID-19 vaccine Moderna and AZD1222 from Astra Zeneca) [7–9] until March 16th, 2021. Between December 13th, 2020 to March 16th, 2021 (94 days), 361 734 967 people received vaccination in international COVID-19 vaccination dataset [10] and 2161 thrombotic events (795 venous and 1374 arterial thrombotic event) were reported in Vigibase on March 16th, 2021. Spontaneous reports of thrombotic events are shared in 1197 for Comirnaty, 325 for COVID-19 vaccine Moderna and 639 for AZD1222 vaccine (table 1). With these data, we were able to evaluate a reporting rate for venous (VTE) and arterial (ATE) thrombotic events cases during the time period (94 days) among the total number of people vaccinated using formula: number of thrombotic cases in the given time period divided by the total numbers of vaccinated person-days at risk during the same period. Thus, the rate was 0.21 [95% CI: 0.19–0.22] cases of thrombotic events per 1 million person vaccinated-days. For VTE and ATE, rates were respectively 0.075 [95% CI: 0.07–0.08] and 0.13 [95% CI: 0.12–0.14] cases per 1 million person vaccinated-days.

View this table:
TABLE 1

Clinical characteristics of patients described in the World Health Organisation database of individual case safety reports, performed at the Uppsala Drug Monitoring Centre until March 16th for the three vaccine Comirnaty® from Pfizer-BioNtech, COVID-19 vaccine Moderna and Oxford-AstraZeneca vaccine

First and foremost, we have been recording an imbalance between VTE and arterial thrombotic ATE in mRNA vaccines, respectively 31.8% (381/1197) and 67.9% (813/1197) for Comirnaty; 24.6% (80/325) and 77.6% (253/325) for Moderna vaccine. Conversely, for AZD1222 we have been noticing a proportion of VTE and ATE evenly shared (52.2% (334/639) versus 48.2%) (308/639) respectively). The timeframe between vaccination and ATE is the same for three vaccines (median of 2 days), whereas we identified a significant difference between AZD1222 (median of 6 days) and both mRNA vaccines (median of 4 days with p=0.007 and 0.02, respectively for Comirnaty and Moderna vaccine) for VTE. Concerning ATE, the patients’ profile for the three vaccines appear to be similar.

Moreover, we observed unexpected cerebral venous thrombosis (CVT) for COVID-19 vaccine Moderna (0.9% (3/325) of events reported; time to event: 2 to 39 days; range: 30–37 years-old; 3 women), for AZD1222 (1.1% (7/639) of events reported; time to event: 2 to 16 days; range: 19–59 years-old; 3 women and 4 men) and with Comirnaty (0.4% (4/1197) of events reported; time to event: 1–10 days; range:30–84 years-old; 4 women). Three patients out of four with Comirnaty, all Moderna vaccine and six out of seven with AZ1222 had a particular form of CVT, called cerebral sinus vein thrombosis (CVST). Five out of seven CVT cases observed after AZD1222 were associated to thrombocytopenia. Moreover, we noticed thrombocytopenia associated to thrombotic events and/or disseminated intravascular coagulation and/or antiphospholipids antibodies for all three vaccines and one thrombocytopenia associated with HIT positive tests after AZD1222. Since we performed extraction of the WHO database, several other cases of HIT has been described by two groups after AZ1222 vaccination [11, 12]. They proposed to name this phenomenon Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).

There are several limitations in our data presented here. First, for pharmacovigilance purpose, the appropriate term is reporting rate. Incidence or prevalence are not appropriate since we have no information about precise denominator for each separate vaccine and about the extent of underreporting. Indeed, these pharmacovigilance spontaneous reports are part of the post marketing surveillance for drugs and underreporting of ADRs is well known [13]. In a published study, the median underreporting rate across 37 studies included was 94% (interquartile range 82–98%) even for serious/severe ADRs.

Second, the best way to evaluate thrombotic events in the vaccinated population should be to match to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics [14]. However, ADRs reported in VigiBase do not allow us to have this kind of paired data. Third, we could have an unusual reporting because of the novelty of the vaccine. Indeed, studies design may modify reporting of ADRs [15]. Open-label studies have been described to overestimate the risk of vascular adverse events by at least 50% in contrast to double blind randomised trials [15]. Pharmacovigilance spontaneous reporting is different from clinical trials but probably close to open-label studies for potential unusual estimation of thrombotic events that could be influenced by novelty of the drug, media interest and/or conflicting results in literature.

All in all, our data represents a hypothesis-generating study suggesting that thrombotic events, including CVT, might occur in association with all three vaccines, but this hypothesis requires further investigations including extensive clinical and biological studies. Benefits of the vaccine is a non-discussion point in COVID-19 outbreak epidemiology. However there is an urgent need for a prospective evaluation of coagulopathy and thrombotic events to fathom rare but serious side effects after COVID-19 vaccination and better characterise VIPIT and other thrombocytopenia associated or not with thrombotic events after the three vaccines.

Acknowledgement

this publication describes information obtained from VigiBase. VigiBase, has information coming from a variety of sources, and the probability that the suspected adverse effect is drug-related is not the same in all cases. This information does not represent the opinion of the UMC or the World Health Organisation.

Footnotes

  • Support statement: David M. Smadja'COVID team has been funded with grants from the French national agency for research ANR SARCODO (Fondation de France) and Mécénat Covid AP-HP. Assistance Publique – Hôpitaux de Paris; DOI: http://dx.doi.org/10.13039/501100002738; Grant: Mécénat COVID; Fondation de France; DOI: http://dx.doi.org/10.13039/501100004431; Grant: SARCODO; Agence Nationale de la Recherche; DOI: http://dx.doi.org/10.13039/501100001665; Grant: SARCODO.

  • Conflict of interest: Dr. Smadja reports personal fees from carmat, non-financial support from Boehringer ingelheim, personal fees from Bayer, personal fees from BMS, personal fees from Aspen, personal fees from Leo Pharma, outside the submitted work; .

  • Conflict of interest: Dr. Yue has nothing to disclose.

  • Conflict of interest: Dr. Chocron reports personal fees from Aspen, outside the submitted work; .

  • Conflict of interest: Dr. Sanchez reports grants from Bayer, grants from Daichi sankyo, grants from Portola pharmaceuticals, personal fees from Actelion, personal fees from GlaxoSmithKline, personal fees from Boerhinger Ingelheim, personal fees from Chiesi, non-financial support from Leo Pharma, outside the submitted work; .

  • Conflict of interest: Dr. Lillo le-louet has nothing to disclose.

  • Received March 31, 2021.
  • Accepted April 13, 2021.
  • ©The authors 2021.
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Philippe A,
    2. Chocron R,
    3. Gendron N, et al.
    Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality. Angiogenesis 2021.
    1. Jevnikar M,
    2. Sanchez O,
    3. Chocron R, et al.
    Prevalence of pulmonary embolism in patients with COVID 19 at the time of hospital admission. Eur Respir J 2021.
    1. Huertas A,
    2. Montani D,
    3. Savale L, et al.
    Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir J 2020; 56. doi:10.1183/13993003.01634-2020
  2. ↵
    1. Chocron R,
    2. Galand V,
    3. Cellier J, et al.
    Anticoagulation prior to hospitalisation is a potential protective factor for COVID-19: insight from a French multicenter cohort study. J Am Heart Assoc 2021: e018288.
  3. ↵
    1. Bate A,
    2. Lindquist M,
    3. Edwards IR, et al.
    A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315–321. doi:10.1007/s002280050466
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Barker CI,
    2. Snape MD
    . Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014; 14: 227–238. doi:10.1016/S1473-3099(13)70238-X
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Polack FP,
    2. Thomas SJ,
    3. Kitchin N, et al.
    Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–2615. doi:10.1056/NEJMoa2034577
    OpenUrlCrossRefPubMed
    1. Baden LR,
    2. El Sahly HM,
    3. Essink B, et al.
    Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–416. doi:10.1056/NEJMoa2035389
    OpenUrlCrossRefPubMed
  6. ↵
    1. Voysey M,
    2. Costa Clemens SA,
    3. Madhi SA, et al.
    Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397: 881–891. doi:10.1016/S0140-6736(21)00432-3
    OpenUrl
  7. ↵
    https://ourworldindata.org/covid-vaccinations [Internet]. 2021
  8. ↵
    1. Greinacher A,
    2. Thiele T,
    3. Warkentin TE, et al.
    Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 2021.
  9. ↵
    1. Schultz NH,
    2. Sorvoll IH,
    3. Michelsen AE, et al.
    Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021.
  10. ↵
    1. Hazell L,
    2. Shakir SA
    . Under-reporting of adverse drug reactions : a systematic review. Drug Saf 2006; 29: 385–396. doi:10.2165/00002018-200629050-00003
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Dagan N,
    2. Barda N,
    3. Kepten E, et al.
    BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021.
  12. ↵
    1. Trone JC,
    2. Ollier E,
    3. Chapelle C, et al.
    Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events-a meta-analysis. Ann Oncol 2018; 29: 803–811. doi:10.1093/annonc/mdy035
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 62 Issue 3 Table of Contents
European Respiratory Journal: 62 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase
David M. Smadja, Qun-Ying Yue, Richard Chocron, Olivier Sanchez, Agnes Lillo-Le Louet
European Respiratory Journal Jan 2021, 2100956; DOI: 10.1183/13993003.00956-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase
David M. Smadja, Qun-Ying Yue, Richard Chocron, Olivier Sanchez, Agnes Lillo-Le Louet
European Respiratory Journal Jan 2021, 2100956; DOI: 10.1183/13993003.00956-2021
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgement
    • Footnotes
    • References
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Derivation of a high-resolution CT-based, semi-automated radiographic score in tuberculosis and its relationship to bacillary load and antitubercular therapy
  • Translated impact on carbon footprint from choice of inhaled therapy: a Danish scenario
  • Regular, low-dose, sustained-release morphine for persisting breathlessness in interstitial lung disease - a randomised, double-blind, placebo-controlled, crossover trial
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society